Clinical Trials Directory

Trials / Completed

CompletedNCT06547346

Acceptability and Palatability Study of Paediatric Amino Acid Feed

To Evaluate the Acceptability and Palatability of a Hypoallergenic Nutritionally Complete Powdered Amino Acid Formula With HMO (Human Milk Oligosaccharides) for the Dietary Management of Cows' Milk Allergy (CMA) and Multiple Food Protein Allergies (MFPA) in Children Over ≥1 Year.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Société des Produits Nestlé (SPN) · Industry
Sex
All
Age
1 Year – 16 Years
Healthy volunteers
Not accepted

Summary

Product acceptability and palatability data from a minimum of 15 participants are required to submit an application to the Advisory Committee on Borderline Substances (ACBS) and the Health Service Executive (HSE) for Ireland for product registration

Detailed description

The study product, Alfamino Junior (neutral or vanilla flavour) is a is a food for special medical purposes, as defined by EU Regulation No 609/2013, ACBS approved, prescribable on FP10 (GP10 in Scotland). Alfamino Junior (neutral or vanilla flavour) is is for complete nutritional support of children ≥1 year with cows' milk allergy, multiple food allergies and other conditions where an amino acid formula is recommended. This is an open label nonrandomised acceptability, palatability and compliance study to evaluate the tolerance of the study formulas in 15 children. Palatability is recorded over a 7day study period, acceptability is recorded days 1-7 and days 22-28 of the study period, with patient compliance recorded over the full 28 day study period

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTAlfamino JuniorTo recruit 15 children and evaluate the acceptability (including gastrointestinal tolerance), palatability and compliance of a hypoallergenic amino acid powdered formula (neutral and vanilla flavours) with HMO's for the dietary management of presumed cows' milk allergy, multiple food protein allergies and other conditions where an amino acid formula is recommended in children ≥1 year of age.

Timeline

Start date
2024-01-05
Primary completion
2024-12-15
Completion
2024-12-16
First posted
2024-08-09
Last updated
2024-12-27

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT06547346. Inclusion in this directory is not an endorsement.